Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$27.24
+1.1%
$37.59
$11.20
$72.98
$6.05B1.6515.29 million shs18.47 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$841.70
+14.5%
$829.56
$677.09
$972.53
$798.08B0.513.42 million shs10.84 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$57.99
-7.8%
$76.03
$57.28
$148.15
$260.23B0.615.96 million shs32.19 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+1.19%+1.70%-13.40%-2.02%+120.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+14.54%+16.93%+2.44%+15.90%+12.10%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-7.78%-5.11%-28.37%-26.35%-53.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.5858 of 5 stars
4.12.00.00.02.03.31.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8318 of 5 stars
3.43.03.34.03.92.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.617 of 5 stars
4.23.02.50.03.20.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.21
Hold$38.2540.41% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,012.0020.23% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.40
Hold$135.00132.80% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.00
4/15/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy ➝ Underperform
4/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$973.00 ➝ $928.00
4/10/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$39.00 ➝ $33.00
4/9/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,146.00 ➝ $1,124.00
4/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00
4/2/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell
3/18/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$21.00 ➝ $22.00
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B4.10N/AN/A$1.61 per share16.92
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.72$13.72 per share61.34$15.05 per share55.93
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B0.90$2.69 per share21.57$4.64 per share12.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5461.9152.39N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7171.8827.051.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2917.6312.440.9034.81%84.68%26.29%5/7/2025 (Estimated)

Latest NVO, LLY, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92N/AN/AN/A$79.17 billionN/A
5/5/2025Q1 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.11N/AN/AN/A$535.21 millionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.71%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.632.81%+25.26%49.54%N/A

Latest NVO, LLY, and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650222.17 million179.79 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

BMO Capital Downgrades Novo Nordisk A (NVO)
Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital
Novo Nordisk price target lowered to DKK 700 from DKK 900 at Barclays

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$27.24 +0.29 (+1.08%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$27.34 +0.09 (+0.35%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$841.70 +106.80 (+14.53%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$841.10 -0.61 (-0.07%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$57.99 -4.89 (-7.78%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$58.73 +0.74 (+1.28%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.